ProKidney (NASDAQ: PROK)
$2.41
(3.9%)
$0.09
Price as of August 22, 2025, 3:58 p.m. ET
ProKidney Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
ProKidney Company Info
ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of proprietary cell therapy platform. The firm focuses on the treatment of chronic kidney disease (CKD), shifting the emphasis away from management of kidney failure, to the restoration of kidney function to stop or delay progression of CKD. It offers REACT, a product candidate that includes selected renal cells (SRCs) prepared from a patient’s own, autologous, renal cells. The company is headquartered in Winston-Salem, NC.
News & Analysis
Featured Article
ProKidney Reports 78 Percent Gain in Q2
Motley Fool Markets Team | Aug 12, 2025
Featured Article
Meet the Biotech Stock That Rocketed 775% Higher
Cory Renauer | Jul 22, 2025
This Biotech Stock Jumped Over 600% in Just Days After Releasing Promising Clinical Trial Data. And Its Market Cap Is Still Only $2 Billion. But Is It a Buy?
David Jagielski | Jul 17, 2025
Why Shares of ProKidney Were Dropping Thursday
James Halley | Oct 12, 2023
Two factors led to the stock's slide on Thursday.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.